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Hazard ratio (95% conﬁdence interval),
EES vs SES P-value
MACE
Intervention strategy
2-stent technique 0.23 (0.07 – 0.74) 0.013
1-stent technique 1.30 (0.69 – 2.48) 0.42
LM bifurcation
Yes 0.45 (0.19 – 1.06) 0.067
No 1.04 (0.51 – 2.11) 0.918
TVR
Intervention strategy
2-stent technique 0.25 (0.08 – 0.80) 0.019
1-stent technique 1.15 (0.56 – 2.36) 0.703
LM bifurcation
Yes 0.33 (0.12 – 0.93) 0.036
No 1.03 (0.49 – 2.18) 0.934
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of the Axxess stent in bifurcation lesions.The low rate of events shows that the Axxess
dedicated stent is a good choice in treating bifurcation lesions.
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Background: Side branch (SB) occlusion is a serious complication during percuta-
neous coronary intervention (PCI) for bifurcation lesions. This study sought to
investigate the predictors and outcomes of SB occlusion after main vessel (MV)
stenting in coronary bifurcation lesions.
Methods: Consecutive patients undergoing PCI using drug-eluting stents for bifur-
cation lesions with SB 2.3 mm were enrolled. We selected patients treated with 1-
stent technique or MV stenting ﬁrst strategy. SB occlusion after MV stenting was
deﬁned as Thrombolysis in Myocardial Infarction ﬂow grade <3.
Results: SB occlusion occurred in 187 (8.4%) of 2227 bifurcation lesions. In multi-
variate analysis, independent predictors of SB occlusion were preprocedural percent
diameter stenosis of the SB 50% (odds ratio [OR] 2.34; 95% conﬁdence interval
[CI] 1.59-3.43; p<0.001) and the proximal MV 50% (OR 2.34; 95% CI 1.57-3.50;
p<0.001), SB lesion length (OR 1.03; 95% CI 1.003-1.06; p¼0.03), and acute
coronary syndrome (OR 1.53; 95% CI 1.06-2.19; p¼0.02). Of 187 occluded SBs, ﬂow
was restored spontaneously in 26 (13.9%) and by SB intervention in 103 (55.1%), but
not in 58 (31.0%). Jailed wire in the SB was associated with ﬂow recovery (74.8%
versus 57.8%, p¼0.02). Cardiac death or myocardial infarction occurred more
frequently in patients with SB occlusion than those without SB occlusion (adjusted
hazard ratio 2.34; 95% CI 1.15-4.77; p¼0.02).
Conclusions: Angiographic ﬁndings of the SB, proximal MV stenosis, and clinical
presentation are predictive of SB occlusion after MV stenting. Occlusion of sizable SB
is associated with adverse clinical outcomes.
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Background: Treatment of coronary bifurcation lesions represents a challenging area
in interventional cardiology. When compared with nonbifurcation interventions,
bifurcation interventions have a lower rate of procedural success, higher procedural
costs, longer hospitalization, and a higher rate of clinical and angiographic restenosis.
A few small scale studies have reported promising immediate and mid-term results of
drug-coated balloon (DCB) compared to non-coated balloon or a mixed strategy of
DCB and bare metal stent in bifurcation lesions. We analyzed and compared the
safety, focused on the rates of late coronary thrombosis (LT), and the clinical follow-
up after DCB in bifurcation lesions without additional stenting - the so called “Drug-
eluting balloon (DEB) only strategy” in a clinical setting.
Methods: A retrospective review was done of 85 consecutive patients who underwent
percutaneous coronary intervention procedure in de-novo lesions with the paclitaxel
eluting balloon SeQuent Please at a high-volume Heart Center in Potsdam. DCB
was used for the treatment of bifurcation lesions in 38 patients in 38 interventions.
Dual antiplatelet therapy with aspirin and clopidogrel/prasugrel (DAPT) was recom-
mended after DCB angioplasty.
Results: Most represented Medina type was 0/0/1 (36.8%). The procedure was
successful in all patients. Additional stenting of the main branch was needed in 3
(7.9%) interventions. No MACE (cardiac death, myocardial infarction, target lesion
revascularization) occurred up to 30 days. Within 12 months after intervention none of
the patients (0%) patients needed a target lesion revascularization or had suffered from
coronary thrombosis. Duration of DAPT was 4.2  3.8 months.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: The DEB only strategy is a treatment option for patients with bifur-
cation lesions and offers favorable results regarding procedural success, a low risk of
coronary late thrombosis and a low rate of target lesion revascularization.
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Background: Although drug-eluting stents (DES) have markedly broadened indica-
tions for percutaneous coronary intervention (PCI), bifurcation lesion still remains
a challenge. We sought to evaluate the efﬁcacy and safety of everolimus-eluting stent
(EES) for the treatment of bifurcation coronary lesions in comparison to SES (siro-
limus-eluting stent).
Methods: We analyzed the large-scale Korean multi-center registry for bifurcated
coronary lesions, COBIS (Coronary Bifurcation Stenting) II registry. In this registry,
1,762 patients treated with EES (n ¼ 348) or SES (n ¼ 1,414) were enrolled.
Primary outcome was major adverse cardiac events (MACE), deﬁned as a composite
of cardiac death, nonfatal myocardial infarction, and target vessel revascularization
(TVR).
Results: In all bifurcation lesions, EES was comparable to SES regarding MACE,
cardiac death, and TVR rates in the overall population as well as in the 1:3 propensity
score-matched one within 2-year follow-up. However, in speciﬁc subpopulation such
as patients with left main (LM) bifurcation lesions or those treated with 2-stent
technique (table), EES was superior to SES in terms of TVR and MACE rate in the
matched population. The interaction between the type of drug eluting stents and the
intervention strategy was signiﬁcant for both MACE (P ¼ 0.011) and TVR (P ¼
0.030). There was no difference in clinical outcomes between the 2 DESs in non-LM
bifurcation lesions or in patients treated with 1-stent technique.Conclusions: In this large-scale Korean multi-center registry for bifurcated coronary
lesions, EES was superior to SES in patients undergoing complex bifurcation inter-
vention, such as LM bifurcation or two-stent technique PCI.
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Background: It has been unknown whether intentional effort to minimize residual
stenosis of side branch (SB) during percutaneous coronary intervention (PCI) for
coronary bifurcation lesion will improve long-term clinical outcomes or not.acts/POSTER/Bifurcation and Left Main Interventions B123
TUESDAY, OCTOBER, 29, 2013, 3:30 PM–5:30 PM www.jacctctabstracts2013.com
P
O
S
T
E
R
STherefore, we sought to compare long-term clinical outcomes in patients with or
without jailed SB after coronary bifurcation stenting.
Methods: We evaluated 664 patients who underwent successful PCI with DES for
coronary bifurcation lesions from Sejong General Institute PCI database registry
between April 2003 and December 2010. The patients who experienced PCI for left
main bifurcation (n¼146) and with 2 stent technique (n¼55) were sequentially
excluded. The primary endpoint was major adverse cardiac events (MACE), deﬁned
as the composite outcomes of cardiac death, non-fatal myocardial infarction (MI) and
target lesion revascularization. Quantitative coronary angiography was performed in
all study population. The jailed SB was deﬁned as  50% residual stenosis after main
vessel (MV) stenting.
Results: Three-hundred ﬁfty ﬁve patients (76.7%) had not jailed SB, and one hundred
eight patients (23.3%) had it. Jailed group had higher rates of triple vessel disease, true
bifurcation lesion, and SB predilation, and lower rate of ﬁnal kissing balloon dilation,
compared to No- jailed group. Also, Jailed group had longer MV and SB lesion
length. During follow-up (median 34 months), MACE occurred in 37 patients (8.0 %);
10 (9.3%) in the jailed group and 27 (7.6 %) in the No-jailed group (P¼0.56 by log-
rank test). In multivariate analysis, jailed SB was not associated with a higher inci-
dence of MACE (hazard ratio [HR]: 0.69, 95% conﬁdence interval [CI]: (0.32-1.48).
If jailed SB was deﬁned as  75% residual stenosis, jailed SB was still not associated
with a higher incidence of MACE (hazard ratio [HR]: 0.97, 95% conﬁdence interval
[CI]: (0.28-3.35)
Conclusions: Our registry data suggest only angiographic severity of residual stenosis
in SB after MV stenting cannot predict long-term clinical outcome in patients with
coronary bifurcation lesion.TCT-395
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Background: Studies have reported the safety and efﬁcacy of Absorb - BVS in Type
A lesions. We present our initial experience of using Absorb in bifurcation lesions.
Methods: From December 2012 to June 2013, we have treated from 9 patients with
12 bifurcation lesions using ABSORB BVS using different strategies. Of these LAD/
diagonal were seen in 8 patients, LCx /OM 3 patients and RCA in 1 patient. The type
of bifurcation were Medina 1, 1, 1 - 4 (33.33); 1, 0, 0 – 4 (33.33 %); 1, 1, 0 – 2 (16.66
%); 0, 0, 1 – 1 (8.33%) and 0,1,1 (8.33 %).
Results:We classiﬁed bifurcation treatment as, B0 (Single wire in main branch, no wire
in side branch), B1 (2 wires in main and side branch and no balloon dilatation of side
branch), B2 (2 wires in main and side branch with balloon dilatation of the side branch
and B3 (2 wires in main and side branch and another scaffold in the side branch). In B2
and B3 cases, we adopted either high pressure snuggle or low pressure kissing balloon
dilatation. Our treatment strategy was B0 – 4 (33.33 %), B1- 5 (41.66 %), B2- 2
(16.66%), B3 - 1 (8.33%). OCT guidance was used in 5 patients (55.55%). Two patients
were treated with B2, of that one had a snuggle dilatation and the other low pressure
kissing. One patient treated with B3 had 2 scaffolds both deployed in LAD and diagonal
using TAP technique and ﬁnal high pressure snuggle. Immediate outcome were good in
all the patients with TIMI III ﬂow, no signiﬁcant residual lesions and no MACE during
hospital stay. There were no scaffold thrombosis orMACE at 30 days clinical follow up.
Conclusions: Our initial experience in small group using ABSORB BVS in bifur-
cation lesions with different strategies showed it is safe to jail the side branch even
without intervention to the side branch. Provisional T stenting strategy and in selected
cases TAP technique is feasible with OCT showing optimal deployment with good
immediate and 30 day outcome will be presented. The strategy of ﬁnal low pressure
kissing balloon vs high pressure snuggle needs to be studied further although high
pressure snuggle has shown promising immediate outcome with good apposition seen
by OCT imaging.TCT-396
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Background: Everolimus eluting ABSORB bioresorbable vascular scaffold (BVS)
represents a novel approach for PCI with transient vessel support and drug delivery
without the long term limitations of metallic DES. It has been approved for unre-
stricted clinical use in many countries including India since late 2012. However
concern exists regarding its use in Bifurcation lesions (BL) and it has been recom-
mended to avoid using across side branch (SB)  2.00 mm. As nearly 20% of the
percutaneous coronary intervention (PCI) are performed for BL, we present on the ﬁrst
experience of the use of ABSORB BVS in BL from our real world “Real ABSORB
Registry”.
Methods: Our “Real ABSORB Registry” is a single centre registry of all BVS
implanted in real life patients since its approval for unrestricted clinical use from
December 2012 onwards.B124 JACC Vol 62/18/Suppl B j October 27–November 1, 2Results: Out of the 108 patients with 136 lesions, 184 BVS was implanted. Among
them 48 patients had Bifurcation lesions treated with 64 BVS. 58% had Medina 1,1,1 ,
33% had 1,1,0 and 9% had 1,0,1 lesions.7/48 (14.5%) patients were planned for two
stent strategy (V stenting in 2 & T stenting in 5) and 41/48 (85.5%) patients were
planned for provisional single stent strategy. Side branch protected with wire and
jailed in 32/48 (66%) patients. SB re crossed through BVS cells in 20/32 (62.5%)
patients.In 12/20 (60%) patients low pressure simultaneous inﬂation of MB and SB
(SNUGGLE inﬂation) done. 3/12 (25%) patients had threatened closure of SB
following Snuggle inﬂation and had SB stenting with BVS using TAP technique. BVS
deployment was successful in all patients and optimal deployment conﬁrmed in 10/48
(20.8%) using OCT. No MACE including Target lesion failure (TLF)and Target
lesion revascularization (TLR) occurred to discharge nor to current clinical follow up
(median 143 days, range 17-163)
Conclusions: Our Real life experience of BVS implantation in bifurcation lesions
with a major SB suggests that use of ABSORB BVS is feasible with successful
deployment and favorable short to mid term follow up. SB access, optimization and
salvage is feasible while stenting Main branch with ABSORB BVS.
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Background: PCI for ULMCA has recently been upgraded to class-IIB indication in
ACC/AHA guidelines. ULMCA disease is frequently associated with distal disease.
However, there are no available data to compare the long-term clinical outcomes in
patients undergoing PCI of ULMCA disease and achieving CR or ICR.
Methods: A total of 910 consecutive patients with ULMCA disease undergoing DES
implantation were prospectively enrolled in the study. Angiographic CR was deﬁned
as revascularization in all diseased segments with diameter 1.5mm (CR-1, according
to the Synergy between PCI with Taxus and cardiac surgery [SYNTAX] classiﬁca-
tion) or 2.5mm (CR-2). Reasonable ICR (R-ICR) was deﬁned as patients having
a diameter stenosis 50% post treatment in diseased segments with diameter between
1.5mm and 2.5mm. The primary endpoint was the incidence of major cardiac adverse
event (MACE: a composite of cardiac death, myocardial infarction [MI] and target
vessel revascularization) at 5-year follow-up.
Results: Angiographic CR-1 was achieved in 386 (42.4%) patients and CR-2 in 613
(67.4%) patients. Patients with ICR had worse outcomes than those that had CR
(MACE: 26.5% vs. 15.5%, p<0.001; all-cause death: 10.1% vs. 6.2%; p¼0.037 in
CR-1 stratiﬁcation; and MACE: 29.6% vs. 18.1%, p<0.001; all-cause death: 12.5%
vs. 6.5%; p¼0.003 in CR-2 stratiﬁcation). Patients with CR or R-ICR (n¼277, 24.9%)
had no difference in mortality (7.0% vs. 6.2%, p¼0.69), though R-ICR group had
higher incidence of MACE, largely driven by repeat revascularization. On multivariate
analysis, the SYNTAX score and presence of multivessel disease and chronic total
occlusion were independent predictors of ICR. Finally, patients with ICR in distal LM
lesions (n¼32, 3.5%) had substantially poor outcome and most of events occurred
within the ﬁrst year follow-up.
Conclusions: Angiographic ICR has a negative impact on long-term clinical
outcomes in the patients with ULMCA disease treated with DES. R-ICR showed
similar safety compared with the strategy of revascularized all diseased vessels with
diameter 1.5mm and may indeed be optimal revascularization strategy in certain
patient groups.
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Background: The anatomical, clinical, and procedure-based NERS score was supe-
rior to the SYNTAX score in predicting MACEs after stenting UPLMCA. The
complexity of the calculation was its major limitation.
Methods: The NERS score II was derived from our previous two studies and
externally compared with the NERS and SYNTAX scores in 1463 patients with
UPLMCA who underwent implantation of a DES in a prospective, multicenter,
registry trial. The primary end point was MACEs at one year after the index013 j TCT Abstracts/POSTER/Bifurcation and Left Main Interventions
